ConductScience.org, home

Paper36914702

Design and synthesis of novel cytotoxic fluoroquinolone analogs through topoisomerase inhibition, cell cycle arrest, and apoptosis.

Elanany MA and 3 others. Sci Rep, 2023. Cited by 24 papers, by iCite.

Cite this record

ConductScience Library. Design and synthesis of novel cytotoxic fluoroquinolone analogs through topoisomerase inhibition, cell cycle arrest, and apoptosis. Papers, record 36914702. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36914702

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Design and synthesis of novel cytotoxic fluoroquinolone analogs through topoisomerase inhibition, cell cycle arrest, and apoptosis.
PubMed
Journal
Sci Rep
PubMed
Year
2023
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
24
iCite
Relative citation ratio, by iCite
3.72
iCite
Revised in PubMed
2023-04-18
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Elanany MAMohamed A
2Osman EEAEssam Eldin A
3Gedawy EMEhab Mohamed
4Abou-Seri SMSahar M

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
FluoroquinolonesMajor topic
Antineoplastic AgentsMajor topic
Humans
Molecular Structure
Structure-Activity Relationship
Moxifloxacin
Cell Proliferation
Cell Cycle Checkpoints
Cell Line, Tumor
Ciprofloxacin
Apoptosis
Ofloxacin
Drug Screening Assays, Antitumor
Cell Cycle

Source PubMed

Download CSV of topics

References55

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134419964Levofloxacin exerts broad-spectrum anticancer activity via regulation of THBS1, LAPTM5, SRD5A3, MFAP5 and P4HA1.Anticancer Drugs2022https://conductscience.org/library/papers/34419964PubMed
22041050Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.J Natl Cancer Inst1991https://conductscience.org/library/papers/2041050PubMed
311990855DNA and its associated processes as targets for cancer therapy.Nat Rev Cancer2002https://conductscience.org/library/papers/11990855PubMed
461966Flow cytofluorometric analysis of cell cycle distributions using propidium iodide. Properties of the method and mathematical analysis of the data.J Cell Biol1976https://conductscience.org/library/papers/61966PubMed
530528372Moxifloxacin as an inducer of apoptosis in melanoma cells: A study at the cellular and molecular level.Toxicol In Vitro2019https://conductscience.org/library/papers/30528372PubMed
624220853A high-throughput image-based screen for the identification of Bax/Bak-independent caspase activators against drug-resistant cancer cells.Apoptosis2014https://conductscience.org/library/papers/24220853PubMed
716990858The NCI60 human tumour cell line anticancer drug screen.Nat Rev Cancer2006https://conductscience.org/library/papers/16990858PubMed
834016969Structural basis for allosteric regulation of Human Topoisomerase IIα.Nat Commun2021https://conductscience.org/library/papers/34016969PubMed
99176486The proto-oncogene Bcl-2 and its role in regulating apoptosis.Nat Med1997https://conductscience.org/library/papers/9176486PubMed
106266278
"Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate--polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A.
Anal Biochem1981https://conductscience.org/library/papers/6266278PubMed
1122425922Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients.J Thorac Oncol2012https://conductscience.org/library/papers/22425922PubMed
129794033Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine.Q Rev Biophys1998https://conductscience.org/library/papers/9794033PubMed
1328802125Novel 4/3-((4-oxo-5-(2-oxoindolin-3-ylidene)thiazolidin-2-ylidene)amino) benzenesulfonamides: Synthesis, carbonic anhydrase inhibitory activity, anticancer activity and molecular modelling studies.Eur J Med Chem2017https://conductscience.org/library/papers/28802125PubMed
1426902121Repositioning of antibiotic levofloxacin as a mitochondrial biogenesis inhibitor to target breast cancer.Biochem Biophys Res Commun2016https://conductscience.org/library/papers/26902121PubMed
1516101488Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents2005https://conductscience.org/library/papers/16101488PubMed
169737386Experience with the Vero cell line.Dev Biol Stand1998https://conductscience.org/library/papers/9737386PubMed
179205852Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer.Drugs Aging1997https://conductscience.org/library/papers/9205852PubMed
188953102Pharmacokinetics and pharmacodynamics of newer fluoroquinolones.Clin Infect Dis1996https://conductscience.org/library/papers/8953102PubMed
1930339990Synthesis, theoretical, spectroscopic and electrochemical DNA binding investigations of 1, 3, 4-thiadiazole derivatives of ibuprofen and ciprofloxacin: Cancer cell line studies.J Photochem Photobiol B2018https://conductscience.org/library/papers/30339990PubMed
2032975138DNA topoisomerases as molecular targets for anticancer drugs.J Enzyme Inhib Med Chem2020https://conductscience.org/library/papers/32975138PubMed

See all 55 referencesDownload CSV of references

Cited by14

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.

PMIDTitleJournalYearIn PapersSource
42793155Novel Lomefloxacin-Triazole Hybrids: Design, Synthesis and In Vitro Antiproliferative Activity in Breast, Melanoma and Colon Cancer Cell Lines.Biomolecules2026https://conductscience.org/library/papers/42793155PubMed
42660817Quinoline-Based Scaffolds in Anticancer Drug Discovery: Molecular Targets, Synthetic Strategies, and Biological Advances.ChemMedChem2026https://conductscience.org/library/papers/42660817PubMed
42197495Fluoroquinolone-Induced Metabolic Dysregulation and Oxidative Stress Orchestrate Bacterial Demise.Microorganisms2026https://conductscience.org/library/papers/42197495PubMed
41977249Design, Synthesis, and Bioevaluation of Moxifloxacin Hydrazide Metal Complexes: Integrated Spectroscopic, Computational, Antimicrobial, and Anticancer Investigations.Int J Mol Sci2026https://conductscience.org/library/papers/41977249PubMed
41888388Topoisomerase I/II inhibitors: from established drugs to next-generation therapeutics.Inflammopharmacology2026https://conductscience.org/library/papers/41888388PubMed
41510714Recent Developments in Heterocyclic Derivatives as Novel Cancer Therapeutics: From 2020-2024.Mini Rev Med Chem2026https://conductscience.org/library/papers/41510714PubMed
40469234Vistas in the domain of 3-acetyl-4-hydroxy-2-quinolinone derivatives (AHQ) and their applications.RSC Adv2025https://conductscience.org/library/papers/40469234PubMed
40430482Norfloxacin Derivative with Carbazole at C-7 FQB-1 Induces Cytotoxic, Antiproliferative, and Antitumor Effects in an Experimental Lung Carcinoma Model.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/40430482PubMed
39770435In Silico Evaluation of Some Computer-Designed Fluoroquinolone-Glutamic Acid Hybrids as Potential Topoisomerase II Inhibitors with Anti-Cancer Effect.Pharmaceuticals (Basel)2024https://conductscience.org/library/papers/39770435PubMed
39569131Drug repurposing of fluoroquinolones as anticancer agents in 2023.RSC Adv2024https://conductscience.org/library/papers/39569131PubMed
39191818Evaluating larvicidal, ovicidal and growth inhibiting activity of five medicinal plant extracts on Culex pipiens (Diptera: Culicidae), the West Nile virus vector.Sci Rep2024https://conductscience.org/library/papers/39191818PubMed
38486053Larvicidal activity of Acacia nilotica extracts against Culex pipiens and their suggested mode of action by molecular simulation docking.Sci Rep2024https://conductscience.org/library/papers/38486053PubMed
38357952Ciprofloxacin and Norfloxacin Hybrid Compounds: Potential Anticancer Agents.Curr Top Med Chem2024https://conductscience.org/library/papers/38357952PubMed
38038012Overview of the New Bioactive Heterocycles as Targeting Topoisomerase Inhibitors Useful Against Colon Cancer.Anticancer Agents Med Chem2024https://conductscience.org/library/papers/38038012PubMed

Download CSV of cited by

Genes13

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36914702

GET https://conductscience.org/api/papers/v1/36914702/references?page=2